Melanocytic Hyperactivation Simulating an Acral Lentiginous Melanoma in a Patient With Parkinson Disease Treated by Levodopa.

Related Articles:

• Monthly Research Review – January 2021 January 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during the previous 4 weeks. The post is divided into eight parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• 2021: Wish list January 26, 2021 # # # # Here at the Science of Parkinson’s, we don’t like making predictions – that’s a fool’s game. We would rather focus our attention on interesting ideas and trends, discussing what we hope to see happen in the future, and exploring different ways and means by which change could occur. It is done in the hope that someone…
• The basket case February 10, 2021 # # # # One of the more interesting pieces of clinical trial news in 2020 was the publication of the results of a “basket study” for neurological conditions. This was a trial that involved a drug being tested on a selection of neurodegenerative conditions, rather than just one condition. Between December 2013 to May 2017, researchers recruited a total…
• Being ly-mphatic about drainage issues February 4, 2021 # # # # The lymphatic network is an important part of our body’s defense system. It is made up of an enormous web of vessels and nodes which help to protect us from infection and disease. This network transports a colourless fluid (called lymph), which serves two primary functions: 1.) it contains infection-fighting white blood cells that help in…
• Parkinson’s Patients Have a Higher Risk of Developing Melanoma — and Vice Versa, Study Finds July 7, 2017 Parkinson’s disease patients have a significantly higher risk of developing melanoma, and the opposite is also true, according to a new study. But researchers aren’t sure of the cause. The study, “Parkinson Disease and Melanoma: Confirming and Reexamining an Association,” was published in the journal Mayo Clinic Proceedings. Research dating back to 1972 has examined the correlation between the development…
• Trying to LIMP-2 the lysosome February 8, 2021 # # # # Lysosomes are small bags of enzymes that are used to break down material inside of cells – digesting newly absorbed food or recycling old/used proteins and rubbish. Recently researchers have been discovering increasing evidence that points towards dysfunction in lysosomes as a key influential player in neurodegenerative conditions, like Parkinson’s. There are several Parkinson’s genetic risk…
• Parkinson’s Disease & Risk of Cancer February 12, 2019 Parkinson’s disease and cancer: what’s the connection? Researchers have long tried to understand the relationship between Parkinson’s disease (PD) and cancer, with multiple studies conducted over the years. Intuitively, PD and cancer are not at all similar, and can even be thought of as biochemically opposite – in one disease (PD), cells die unexpectedly and in the other (cancer), cells…
• Treating Parkinson’s with Carbidopa/Levodopa November 27, 2020 “If you are always trying to be normal you will never know how amazing you can be.” Maya Angelou “Hope and fear cannot occupy the same space. Invite one to stay.” Maya Angelou Précis: This blog post’s primary goal is to present an overview of Carbidopa/Levodopa (originally named Sinemet) for treating Parkinson’s. A secondary objective was to describe the change in…
• Treating Parkinson’s with Carbidopa/Levodopa November 27, 2020 “If you are always trying to be normal you will never know how amazing you can be.” Maya Angelou “Hope and fear cannot occupy the same space. Invite one to stay.” Maya Angelou Précis: This blog post’s primary goal is to present an overview of Carbidopa/Levodopa (originally named Sinemet) for treating Parkinson’s. A secondary objective was to describe the change in…
• Monthly Research Review – December 2020 December 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Monthly Research Review – August 2019 August 31, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during August 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• Carbidopa/Levodopa: Answers to the Frequently Asked Questions May 21, 2019 Carbidopa/Levodopa: Answers to the Frequently Asked Questions Loss of neurons in the brain that use dopamine to communicate is one of the hallmark features of Parkinson’s disease (PD), causing slowness, stiffness, tremor and balance problems. Replacing the brain’s dopamine is therefore one of the key treatment strategies to help improve the motor symptoms of PD. Dopamine itself does not cross…
• High lithium levels in tobacco may account for reduced incidences of both Parkinson's disease and melanoma in smokers through enhanced β-catenin-mediated activity. August 25, 2019 Related ArticlesHigh lithium levels in tobacco may account for reduced incidences of both Parkinson's disease and melanoma in smokers through enhanced β-catenin-mediated activity. Med Hypotheses. 2019 Oct;131:109302 Authors: Guttuso T Abstract Parkinson's disease (PD) patients have higher rates of melanoma and vice versa, observations suggesting that the two conditions may share common pathogenic pathways. β-Catenin is a transcriptional cofactor that,…
• The Crazy Hat Lady is Back! June 28, 2019 It’s summer time. Here in Southern California, the June gloom is giving way to the glorious sunshine that California is known for. And all that sunshine brings us both the good and the bad.  It is also time for the return of the Crazy Hat Lady!  My big hats have been dusted off and ready to be worn. The good:…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• The age-associated changes of PARKIN January 28, 2021 # # # # Tiny variations in a region of DNA referred to as “Parkin” are associated with an increased risk of developing Parkinson’s (particularly young onset forms of the conditions). The Parkin DNA provide the instructions for making a protein that is involved with many functions inside cells. New research indicates that as we age, Parkin protein becomes less…
• Our approach to failure February 14, 2021 # # # # Recently the results of two large clinical trials in Parkinson’s were announced. Both indicated that the therapies involved had not demonstrated any impact on the progression of Parkinson’s. This disappointing news resulted in the usual headlines (“Epic failure” & “Clinical trial tanks”) from news outlets whose editors have obviously never lost anyone they cared about. In…
• Abnormal Hyperactivation in the Brain May Be an Early Sign of Alzheimer’s January 21, 2021 Hyperactivation in specific brain areas may be an early biomarker for Alzheimer's disease. Researchers found those who reported concerns over diminished memory skills, and with other risk factors for Alzheimer's, showed signs of hyperactivation in brain areas prior to the diagnosis of dementia.
• Gut Bacteria Affect Metabolism of Parkinson’s Therapy Levodopa, Study Shows January 24, 2019 Levodopa, one of the main medicines used to treat Parkinson’s symptoms, can be converted into dopamine by gut bacteria, researchers report. The findings might explain why levodopa treatment is less effective in some patients. The study, “Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease,” was published in Nature Communications. Parkinson’s disease is characterized by…
• ALS: From ice bucket to centaur November 18, 2020 # # # # Amyotrophic lateral sclerosis (or ALS) is the third most common neurodegenerative condition. It is characterised by the loss of motor neurons, which leads to loss of muscle control. As with Parkinson’s, there is no cure for ALS, and there are only two FDA approved therapies for the condition. Recently, a biotech company – called Amylyx Pharmaceuticals…